Sander Van-Deventer Insider Profile
4 Followers
Sander Van-Deventer, EVP, Research & Product Dev. at uniQure, holds 2.48K shares in Hookipa Pharma (Ticker: HOOK), holds 59.08K shares in uniQure (Ticker: QURE), holds ― shares in Argos Therapeutics (Ticker: ARGSQ).
Sander Van-Deventer's Trading History
| HOOKHookipa Pharma | Oct 23, 2020 | ― | Uninformative Buy | ― | $2.86K | |
| QUREuniQure | Jan 31, 2020 | EVP, Research & Product Dev. | Uninformative Buy | ― | $1.29M | |
| ARGSQArgos Therapeutics | Oct 03, 2016 | ― | Uninformative Buy | ― | ― |
You May Also Like
Sander Van-Deventer insider profile FAQ
What is the percentage of profitable transactions made by Sander Van-Deventer?
The percentage of profitable transactions made by Sander Van-Deventer is 50%.
What is the average return per transaction made by Sander Van-Deventer?
The average return per transaction made by Sander Van-Deventer is -29.70%.
What stocks does Sander Van-Deventer hold?
Sander Van-Deventer holds: QURE, ARGSQ, HOOK stocks.
What was Sander Van-Deventer's most profitable transaction?
Sander Van-Deventer’s most profitable transaction was an Informative Sell of QURE stock on January 30, 2020. The return on the trade was 40.30%.
What is Sander Van-Deventer's role in uniQure?
Sander Van-Deventer's role in uniQure is EVP, Research & Product Dev..
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.
TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.
